Genetic heterogeneity in HER2 testing in breast cancer panel summary and guidelines

Gail H. Vance, Todd S. Barry, Kenneth J. Bloom, Patrick L. Fitzgibbons, David G. Hicks, Robert Brian Jenkins, Diane L. Persons, Raymond R. Tubbs, M. Elizabeth H Hammond

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

• Context.-Intratumoral heterogeneity of HER2 gene amplification has been well documented and represents subclonal diversity within the tumor. The reported incidence of intratumor HER2 amplification genetic heterogeneity ranges in the literature from approximately 5% to 30%. The presence of HER2 genetic heterogeneity may increase subjectivity in HER2 interpretation by the pathologist. Objectives.-To define HER2 genetic heterogeneity and to provide practice guidelines for examining and reporting breast tumors with genetic heterogeneity for improvement of HER2 testing in breast cancer. Design.-We convened an expert panel to discuss HER2 gene amplification testing by fluorescence in situ hybridization. Components addressed included a definition of HER2 amplification heterogeneity, practice guidelines for examination of the tissue, and reporting criteria for this analysis. Results.-Genetic heterogeneity for amplification of HER2 gene status in invasive breast cancer is defined and guidelines established for assessing and reporting HER2 results in these cases. These guidelines are additive to and expand those published in 2007 by the American Society of Clinical Oncology and the College of American Pathologists. Conclusion.-Standardized methods for analysis will improve the accuracy and consistency of interpretation of HER2 gene amplification status in breast cancer.

Original languageEnglish (US)
Pages (from-to)611-612
Number of pages2
JournalArchives of Pathology and Laboratory Medicine
Volume133
Issue number4
StatePublished - Apr 2009

Fingerprint

Genetic Heterogeneity
erbB-2 Genes
Guidelines
Gene Amplification
Breast Neoplasms
Practice Guidelines
Fluorescence In Situ Hybridization
Incidence
Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Vance, G. H., Barry, T. S., Bloom, K. J., Fitzgibbons, P. L., Hicks, D. G., Jenkins, R. B., ... Hammond, M. E. H. (2009). Genetic heterogeneity in HER2 testing in breast cancer panel summary and guidelines. Archives of Pathology and Laboratory Medicine, 133(4), 611-612.

Genetic heterogeneity in HER2 testing in breast cancer panel summary and guidelines. / Vance, Gail H.; Barry, Todd S.; Bloom, Kenneth J.; Fitzgibbons, Patrick L.; Hicks, David G.; Jenkins, Robert Brian; Persons, Diane L.; Tubbs, Raymond R.; Hammond, M. Elizabeth H.

In: Archives of Pathology and Laboratory Medicine, Vol. 133, No. 4, 04.2009, p. 611-612.

Research output: Contribution to journalArticle

Vance, GH, Barry, TS, Bloom, KJ, Fitzgibbons, PL, Hicks, DG, Jenkins, RB, Persons, DL, Tubbs, RR & Hammond, MEH 2009, 'Genetic heterogeneity in HER2 testing in breast cancer panel summary and guidelines', Archives of Pathology and Laboratory Medicine, vol. 133, no. 4, pp. 611-612.
Vance, Gail H. ; Barry, Todd S. ; Bloom, Kenneth J. ; Fitzgibbons, Patrick L. ; Hicks, David G. ; Jenkins, Robert Brian ; Persons, Diane L. ; Tubbs, Raymond R. ; Hammond, M. Elizabeth H. / Genetic heterogeneity in HER2 testing in breast cancer panel summary and guidelines. In: Archives of Pathology and Laboratory Medicine. 2009 ; Vol. 133, No. 4. pp. 611-612.
@article{5b2ab542e2af4070afba169cd9b51bf3,
title = "Genetic heterogeneity in HER2 testing in breast cancer panel summary and guidelines",
abstract = "• Context.-Intratumoral heterogeneity of HER2 gene amplification has been well documented and represents subclonal diversity within the tumor. The reported incidence of intratumor HER2 amplification genetic heterogeneity ranges in the literature from approximately 5{\%} to 30{\%}. The presence of HER2 genetic heterogeneity may increase subjectivity in HER2 interpretation by the pathologist. Objectives.-To define HER2 genetic heterogeneity and to provide practice guidelines for examining and reporting breast tumors with genetic heterogeneity for improvement of HER2 testing in breast cancer. Design.-We convened an expert panel to discuss HER2 gene amplification testing by fluorescence in situ hybridization. Components addressed included a definition of HER2 amplification heterogeneity, practice guidelines for examination of the tissue, and reporting criteria for this analysis. Results.-Genetic heterogeneity for amplification of HER2 gene status in invasive breast cancer is defined and guidelines established for assessing and reporting HER2 results in these cases. These guidelines are additive to and expand those published in 2007 by the American Society of Clinical Oncology and the College of American Pathologists. Conclusion.-Standardized methods for analysis will improve the accuracy and consistency of interpretation of HER2 gene amplification status in breast cancer.",
author = "Vance, {Gail H.} and Barry, {Todd S.} and Bloom, {Kenneth J.} and Fitzgibbons, {Patrick L.} and Hicks, {David G.} and Jenkins, {Robert Brian} and Persons, {Diane L.} and Tubbs, {Raymond R.} and Hammond, {M. Elizabeth H}",
year = "2009",
month = "4",
language = "English (US)",
volume = "133",
pages = "611--612",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "4",

}

TY - JOUR

T1 - Genetic heterogeneity in HER2 testing in breast cancer panel summary and guidelines

AU - Vance, Gail H.

AU - Barry, Todd S.

AU - Bloom, Kenneth J.

AU - Fitzgibbons, Patrick L.

AU - Hicks, David G.

AU - Jenkins, Robert Brian

AU - Persons, Diane L.

AU - Tubbs, Raymond R.

AU - Hammond, M. Elizabeth H

PY - 2009/4

Y1 - 2009/4

N2 - • Context.-Intratumoral heterogeneity of HER2 gene amplification has been well documented and represents subclonal diversity within the tumor. The reported incidence of intratumor HER2 amplification genetic heterogeneity ranges in the literature from approximately 5% to 30%. The presence of HER2 genetic heterogeneity may increase subjectivity in HER2 interpretation by the pathologist. Objectives.-To define HER2 genetic heterogeneity and to provide practice guidelines for examining and reporting breast tumors with genetic heterogeneity for improvement of HER2 testing in breast cancer. Design.-We convened an expert panel to discuss HER2 gene amplification testing by fluorescence in situ hybridization. Components addressed included a definition of HER2 amplification heterogeneity, practice guidelines for examination of the tissue, and reporting criteria for this analysis. Results.-Genetic heterogeneity for amplification of HER2 gene status in invasive breast cancer is defined and guidelines established for assessing and reporting HER2 results in these cases. These guidelines are additive to and expand those published in 2007 by the American Society of Clinical Oncology and the College of American Pathologists. Conclusion.-Standardized methods for analysis will improve the accuracy and consistency of interpretation of HER2 gene amplification status in breast cancer.

AB - • Context.-Intratumoral heterogeneity of HER2 gene amplification has been well documented and represents subclonal diversity within the tumor. The reported incidence of intratumor HER2 amplification genetic heterogeneity ranges in the literature from approximately 5% to 30%. The presence of HER2 genetic heterogeneity may increase subjectivity in HER2 interpretation by the pathologist. Objectives.-To define HER2 genetic heterogeneity and to provide practice guidelines for examining and reporting breast tumors with genetic heterogeneity for improvement of HER2 testing in breast cancer. Design.-We convened an expert panel to discuss HER2 gene amplification testing by fluorescence in situ hybridization. Components addressed included a definition of HER2 amplification heterogeneity, practice guidelines for examination of the tissue, and reporting criteria for this analysis. Results.-Genetic heterogeneity for amplification of HER2 gene status in invasive breast cancer is defined and guidelines established for assessing and reporting HER2 results in these cases. These guidelines are additive to and expand those published in 2007 by the American Society of Clinical Oncology and the College of American Pathologists. Conclusion.-Standardized methods for analysis will improve the accuracy and consistency of interpretation of HER2 gene amplification status in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=64849095162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64849095162&partnerID=8YFLogxK

M3 - Article

VL - 133

SP - 611

EP - 612

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 4

ER -